Thyroid Hormone Receptor β Knockdown Reduces Suppression of Progestins by Activating the mTOR Pathway in Endometrial Cancer Cells

Bingtao Ren, Jieyun Zhou, Yingyi Hu, Ruihua Zhong, Qiaoying Lv, Shuwu Xie, Guoting Li, Bingyi Yang, Xiaojun Chen, Yan ZhuInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

This study reveals that knocking down Thyroid Hormone Receptor Beta (THRB) in type I endometrial cancer (EC) cells enhances their growth and motility, while also reducing the effectiveness of progestin treatments. This resistance appears to be mediated by the activation of the mTOR signaling pathway, suggesting THRB plays a crucial role in how EC cells respond to progestin therapy.

What Problem Does This Paper Address?

Progestin therapy is a key treatment for early-stage endometrial cancer (EC) and atypical hyperplasia, particularly for young patients wishing to preserve fertility. However, a significant challenge is "progestin resistance," where these treatments fail in a substantial portion of patients. While progesterone receptor (PR) and estrogen receptor (ER) status are known factors, they don't fully explain why some ER/PR-positive tumors resist treatment, indicating other unknown factors are at play. This paper investigates the role of thyroid hormone receptors (TRs), specifically TRα and TRβ, as potential contributors to this progestin resistance in EC.

Methods

The researchers employed a multi-pronged approach:

  • Cell Culture: They used two human EC cell lines: RL95-2 (classified as type I, hormone receptor-positive) and KLE (classified as type II, hormone receptor-negative).
  • Gene Silencing: They used small interfering RNA (siRNA) to specifically reduce the expression of THRA (TRα) and THRB (TRβ) in these cell lines.
  • Cell Viability and Motility Assays: Standard CCK-8 assays were used to measure cell proliferation, while transwell migration and invasion assays were performed to assess cell motility.
  • Western Blotting: This technique was used to quantify the protein levels of key signaling molecules, particularly those involved in the Akt/mTOR pathway.
  • Transcriptomic Analysis (RNA-Seq): This was used to identify differentially expressed genes (DEGs) and analyze enriched signaling pathways in THRB-silenced cells treated with progestins.
  • Immunohistochemistry (IHC): This was used to examine the expression levels of TRα and TRβ in endometrial tissues from patients who were either sensitive or resistant to progestin therapy.
  • Serum Analysis: Levels of thyroid hormones (FT3, FT4, TSH) were measured in patients with EC and healthy controls.

Datasets

  • Human Patient Data: Serum samples and endometrial tissues were collected from patients with EC and endometrial atypical hyperplasia (EAH), as well as from healthy controls. Specific numbers are provided for serum (41 EC patients, 67 healthy women) and tissue samples (8 EAH, 12 EC).
  • Cell Lines: Human RL95-2 and KLE EC cell lines were used.

Key Insights and Ideas

  • THRB, Not THRA, is Key: The study strongly suggests that THRB, rather than THRA, is the critical thyroid hormone receptor involved in progestin response in type I EC cells. Silencing THRA had minimal impact, while THRB knockdown significantly altered cell behavior.
  • mTOR Pathway Activation: THRB knockdown appears to "unlock" the mTOR signaling pathway, making EC cells more proliferative and migratory, and crucially, less responsive to the growth-inhibitory effects of progestins.
  • Progestin Resistance Mechanism: The findings propose a novel mechanism for progestin resistance: reduced THRB expression leads to mTOR pathway activation, which then overrides the suppressive effects of progestins.
  • Clinical Relevance: Lower serum T3 levels in EC patients and the correlation between higher TRβ expression and progestin sensitivity in patient tissues lend significant clinical weight to the findings.

Key Results

  • THRB Knockdown Promotes Growth and Motility: In RL95-2 cells (type I EC), THRB silencing significantly increased cell viability and migration. This effect was not observed in KLE cells (type II EC).
  • Progestin Efficacy Reduced: In THRB-silenced RL95-2 cells, the growth-inhibitory effects of progestins (MPA and NOMAc) were significantly attenuated.
  • mTOR Pathway Activation: THRB knockdown, especially when combined with progestin treatment, led to a significant increase in the phosphorylation of mTOR, 4EBP1, and eIF4G in RL95-2 cells. This contrasts with the Akt pathway, which was less consistently affected.
  • Clinical Correlations: Patients with EC showed significantly lower serum T3 levels compared to healthy women. Furthermore, strong TRβ expression was observed in progestin-sensitive endometrial tissues, while TRα expression was less consistently associated with sensitivity.
  • T3's Modulatory Role: Exogenous T3 partially counteracted the progestin-induced activation of the mTOR pathway in THRB-silenced RL95-2 cells, suggesting a complex interplay.

Limitations and Future Work

  • Sample Size: The authors acknowledge that the sample size for patient data (serum and tissue) was small, limiting the generalizability of the clinical findings. They recommend further experimental observation and clinical data collection.
  • Relationship between Progestin Resistance and TR Function: While a correlation is suggested, the precise molecular mechanisms linking progestin resistance and TR function require deeper exploration.
  • Cell Line Specificity: The distinct responses observed between RL95-2 and KLE cells highlight the need for further investigation into why THRB's role might differ between type I and type II EC.
  • Further Exploration of mTOR Pathway: While the mTOR pathway is implicated, a more detailed understanding of how THRB specifically regulates its components in the context of progestin resistance is warranted.

Summary updated

Abstract

Progestin resistance is a major obstacle to conservative therapy in patients with endometrial cancer (EC) and endometrial atypical hyperplasia (EAH). However, the related inducing factor is yet unclear. In this study, thyroid hormone and its receptor α (TRα) and β (TRβ) of patients were assayed. THRB-silenced RL95-2 and KLE EC cells were cultured to investigate the response of progestins. Transcriptomics and Western blotting were performed to investigate the changes in signaling pathways. We found that THRB, rather than THRA, knockdown promoted the viability and motilities of RL95-2 cells but not KLE cells. The suppressive effect of progestins on cell growth and motility significantly decreased in THRB-silenced RL95-2 cells. Multiple proliferation-related signaling pathways were enriched, and the activities of mammalian targets of rapamycin (mTOR)/4e-binding protein 1 (4EBP1)/eukaryotic translation initiation factor 4G (eIF4G) rather than phosphorylated protein kinase B (Akt) were remarkably boosted. Progestin treatment enhanced the effects, and the augmentation was partially abated on supplementation with T3. In THRB-knockdown KLE cells, the progestins-activated partial signaling pathway expression (either mTOR or eIF4G), and supplementation with T3 did not induce noticeable alterations. The serum levels of triiodothyronine (T3) were significantly lower in patients with EC compared with healthy women. A strong expression of TRβ was observed in most patients with EC and EAH sensitive to progestin treatment. In contrast, TRα positive expression was detected in less than half of the patients sensitive to progestin therapy. In conclusion, THRB knockdown enhanced the viability and motility of type I EC cells and attenuated the suppressive effects of progestins by activating the mTOR-4EBP1/eIF4G pathway. Lower expression of THRB is likely correlated with progesterone resistance.
BibTeX
@article{ren2022thyroid,
  author = {Bingtao Ren and Jieyun Zhou and Yingyi Hu and Ruihua Zhong and Qiaoying Lv and Shuwu Xie and Guoting Li and Bingyi Yang and Xiaojun Chen and Yan Zhu},
  title = {{Thyroid Hormone Receptor β Knockdown Reduces Suppression of Progestins by Activating the mTOR Pathway in Endometrial Cancer Cells}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms232012517},
}
Figure